

BIOSPECIFICS TECHNOLOGIES CORP

Form 4

November 04, 2008

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
RA CAPITAL MANAGEMENT,
LLC

(Last) (First) (Middle)

C/O RA CAPITAL
MANAGEMENT, LLC, 800
BOYLSTON STREET, SUITE 1500

(Street)

BOSTON, MA 02199

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol
BIOSPECIFICS TECHNOLOGIES
CORP [BSTC]

3. Date of Earliest Transaction
(Month/Day/Year)
10/30/2008

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____X____ 10% Owner
____ Officer (give title below) ____ Other (specify below)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____ Form filed by One Reporting Person
__X__ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	V	Amount (A) or (D)	Price			
Common Stock	10/30/2008		P		1,000 <u>(1)</u>	A \$ 14	637,444	I	see footnote <u>(2)</u>
Common Stock	10/31/2008		P		5,020 <u>(1)</u>	A \$ 13.5	642,464	I	see footnote <u>(2)</u>
Common Stock	10/31/2008		P		200 <u>(1)</u>	A \$ 14	642,664	I	see footnote <u>(2)</u>
Common Stock	10/31/2008		P		600 <u>(1)</u>	A \$ 14.5	643,264	I	see footnote <u>(2)</u>
	10/31/2008		P		400 ⁽¹⁾	A \$ 15	643,664	I	

Edgar Filing: BIOSPECIFICS TECHNOLOGIES CORP - Form 4

Common Stock								see footnote ⁽²⁾
Common Stock	10/31/2008	P	3,000 ⁽¹⁾	A	\$ 15.5	646,664	I	see footnote ⁽²⁾
Common Stock	10/31/2008	P	200 ⁽¹⁾	A	\$ 16	646,864	I	see footnote ⁽²⁾
Common Stock	10/31/2008	P	580 ⁽¹⁾	A	\$ 16.5	647,444	I	see footnote ⁽²⁾
Common Stock	11/03/2008	P	200 ⁽¹⁾	A	\$ 16	647,644	I	see footnote ⁽²⁾
Common Stock	11/03/2008	P	700 ⁽¹⁾	A	\$ 15	648,344 ⁽³⁾	I	see footnote ⁽²⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director 10% Owner Officer Other
RA CAPITAL MANAGEMENT, LLC C/O RA CAPITAL MANAGEMENT, LLC 800 BOYLSTON STREET, SUITE 1500 BOSTON, MA 02199	X
	X

RA Capital Biotech Fund LP
C/O RA CAPITAL MANAGEMENT, LLC
800 BOYLSTON STREET, SUITE 1500
BOSTON, MA 02199

RA Capital Biotech Fund II, L.P.
C/O RA CAPITAL MANAGEMENT, LLC
800 BOYLSTON STREET, SUITE 1500
BOSTON, MA 02199

X

Kolchinsky Peter
C/O RA CAPITAL MANAGEMENT, LLC
800 BOYLSTON STREET, SUITE 1500
BOSTON, MA 02199

X

ALDRICH RICHARD
C/O RA CAPITAL MANAGEMENT, LLC
800 BOYLSTON STREET, SUITE 1500
BOSTON, MA 02199

X

Signatures

Peter Kolchinsky, Manager of RA Capital Management, LLC

11/04/2008

__Signature of Reporting Person

Date

Peter Kolchinsky, Manager of RA Capital Management, LLC, the General Partner of RA Capital Healthcare Fund, L.P.

11/04/2008

__Signature of Reporting Person

Date

Peter Kolchinsky, Manager of RA Capital Management, LLC, the General Partner of RA Capital Healthcare Fund II, L.P.

11/04/2008

__Signature of Reporting Person

Date

Peter Kolchinsky

11/04/2008

__Signature of Reporting Person

Date

Richard H. Aldrich

11/04/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The acquired shares are divided between RA Capital Healthcare Fund, L.P. ("Fund I") and RA Capital Healthcare Fund II, L.P. ("Fund II") in a ratio of 98.45/1.55.

RA Capital Management, LLC (the "General Partner") is the general partner of both Fund I and Fund II, and Richard H. Aldrich and

(2) Peter Kolchinsky are the sole managers of the General Partner. Each of the Reporting Persons disclaims his or its beneficial ownership of any shares of the above named Issuer reported herein, except to the extent of his or its pecuniary interest therein.

(3) This number represents 640,232 shares held by Fund I and 8,112 shares held by Fund II.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.